ArticlePlant biotechnology journal2025
Characterisation of Early Biosynthetic Steps of Atractylon via an Integrative Strategy.
Article in Plant biotechnology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Chromosome-scale genome assembly and genomic prediction of essential oil compounds in Atractylodes lancea for genomics-assisted breeding.DNA research : an international journal for rapid publication of reports on genes and genomes · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Atractylodes lancea, a vital medicinal plant, is renowned for its bioactive sesquiterpenoids, particularly atractylon. Despite its therapeutic importance, the genetic and biosynthetic pathways underlying atractylon production remain insufficiently understood. In this study, we present a comprehensive chromosome-scale genome assembly of A. lancea with a contig N50 of 263 Mb, advancing the existing genomic knowledge with unprecedented detail. Utilising an integrative omics approach, we coupled genome resequencing across 245 diverse plant accessions, metabolomics and transcriptomics comparisons among different A. lancea genetic backgrounds to profile the sesquiterpenoid divergency and construct a biosynthetic map of the sesquiterpenoids. Metabolite-based genome-wide association studies (mGWAS) reveal significant genetic variations related to atractylon diversity, offering terpene synthase (TPS) gene AlTPSa47 may be involved. Our work further identified and characterised key genes within the TPS family. Catalytic characterisation showed that five of them processed FPP into 12 different sesquiterpenoids. Metabolic profiling determined that transgenic roots overexpressing AlTPSa47 not only increased β-elemene and germacrene B, two of its enzymatic products, but also enhanced atractylon, notably confirming AlTPSa47 is essential in the initial steps of atractylon biosynthesis through rigorous transgenic validation. Collectively, our findings provide foundational resources for advancing breeding programs and enhancing the production of therapeutic compounds in A. lancea, marking a significant leap forward in medicinal plant biotechnology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.